Pivotal Point Tracking NeoGenomics (NEO): AI Cancer Diagnostics Triggers 14% Share Price Surge After Upgraded Annual Forecast
Reading Time: 1 minute
NeoGenomics operates one of the leading networks for molecular and oncological diagnostics in the USA. The company offers highly specialized genetic tests to oncologists, hospitals, and pharmaceutical companies to identify cancers more accurately and develop tailored therapies. On July 29, the corporation surprised with convincing numbers for the second quarter. Revenue increased double digits to approximately 180 million USD. Due to the sustained high demand for complex sequencing tests, management significantly raised the annual forecast for revenue...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
